Becton, Dickinson and Company

(New York Stock Exchange)
Back to all articles
Bullish +55

Becton, Dickinson and Company Yields 2.4%: Is Its Valuation Finally Worth a Look?

Dividend AI-generated analysis

πŸ“ˆ Becton, Dickinson and Company reported Q3 fiscal 2026 revenue growth of 5.4% year over year, reaching $4.98 billion.

πŸ’° Adjusted diluted earnings per share increased 4.9% to $3.23 in the third quarter of fiscal 2026.

πŸš€ The company raised its full-year adjusted EPS guidance midpoint to $12.67, up from $11.90 in fiscal 2025.

πŸ’΅ BDX offers a dividend yield of approximately 2.4% with an annual payout of $4.20 per share.

πŸ“‰ Operating cash flow from ongoing operations rose 33.3% to $2.10 billion in the first nine months of fiscal 2026.

πŸ’Έ Free cash flow increased significantly by 44.6% to $1.73 billion during the same period.

πŸ“Š The stock trades at a forward P/E ratio of 13.72x, which is lower than peers Medtronic and Stryker.

⚠️ Revenue growth remains in low single digits when currency effects are eliminated, requiring margin expansion.

βš–οΈ The company faces potential headwinds from product-related litigation, restructuring, and integration costs.

πŸ”„ BDX separated its Biosciences and Diagnostic Solutions business in February 2026, altering its earnings profile.

Bullish Signals
  • Revenue grew 5.4% year over year to $4.98 billion in Q3 fiscal 2026, demonstrating steady demand for medical devices.
  • Adjusted diluted EPS rose 4.9% to $3.23, leading the company to raise its full-year adjusted EPS guidance midpoint to $12.67.
  • Operating cash flow from ongoing operations surged 33.3% to $2.10 billion in the first nine months of fiscal 2026.
  • Free cash flow increased 44.6% to $1.73 billion, providing strong support for its dividend and future growth initiatives.
  • The stock trades at a forward P/E of 13.72x, which is lower than peers Medtronic (14.93x) and Stryker (16.47x).
  • BDX has a long history of dividend growth, having achieved 54 years of consecutive increases as a Dividend King.
  • The implied payout ratio is around 33% based on fiscal 2026 adjusted EPS guidance, leaving room for reinvestment or debt reduction.
Risk Factors
  • Revenue growth remains in low single digits when currency effects are eliminated, necessitating margin expansion to sustain profitability.
  • The company faces risks from product-related litigation, remediation expenses, restructuring, and integration costs following the business separation.
  • Adjusted earnings must prove sustainable as GAAP profitability could be impacted by non-recurring charges and one-time costs.
Full Analysis
Becton, Dickinson and Company (NYSE: BDX) reported a 5.4% year-over-year revenue increase to $4.98 billion in the third quarter of fiscal 2026, driven by steady demand for its medical devices and exposure to essential healthcare spending. Adjusted diluted earnings per share rose 4.9% to $3.23, leading the company to raise its full-year adjusted EPS guidance midpoint to $12.67, representing approximately 6.5% growth compared to fiscal 2025. The stock currently trades at a forward P/E of 13.72x and offers a dividend yield of roughly 2.4%, with an implied payout ratio around 33% based on the updated guidance. Operating cash flow from ongoing operations surged 33.3% to $2.10 billion in the first nine months of fiscal 2026, while free cash flow jumped 44.6% to $1.73 billion, providing robust support for its dividend and potential for reinvestment or debt reduction. Despite the positive financial metrics, analysts note that revenue growth remains in low single digits even after excluding currency effects, making margin expansion critical. The company faces risks related to product litigation, restructuring costs, and integration expenses following the separation of its Biosciences and Diagnostic Solutions business in February 2026. While the valuation appears discounted relative to some peers like Medtronic and Stryker, sustainability of adjusted earnings is key to realizing long-term value.